Skip to main content
SpringerLink
Log in

Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren

Highlights des ASCO-Kongresses 2015

The most important study results concerning nonsurgical primary treatment of locally advanced head and neck cancer

Highlights of the ASCO Meeting 2015

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Beim jährlichen Treffen der American Society of Clinical Oncology (ASCO) wurden auch 2015 aktuelle Studien zur primären, nichtchirurgischen Therapie lokal fortgeschrittener Kopf-Hals-Tumoren vorgestellt. Bezüglich der konkomitanten Radiochemotherapie (RCT) sind vor allem Studien zur Dosierung und Abfolge der Cisplatingabe aktuell. Darunter wird auch eine Studie zur Dosisreduktion bei auf humanes Papillomavirus (HPV) positiven Patienten vorgestellt. Gegenstand weiterer Untersuchungen sind alternative Substanzen zu Cisplatin, insbesondere Carboplatin und Targettherapeutika. Hinsichtlich der sequenziellen Therapie, also dem Voranstellen einer Induktionschemotherapie (ICT) vor einer RCT, steht weiterhin der Vergleich zur alleinigen RCT im Vordergrund. Darüber hinaus werden jedoch auch Studien vorgestellt, die die Zusammensetzung der ICT variieren oder die nachfolgende Radiotherapie (RT) mit dem Epidermal-Growth-Factor-Receptor(EGFR)-Antikörper Cetuximab kombinieren. In diesem Artikel wird ein Überblick über die wichtigsten, dort vorgestellten Studien gegeben.

Abstract

At the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015, results of current trials dealing with nonsurgical primary treatment of locally advanced head and neck cancer were presented. Regarding concomitant chemoradiotherapy (CRT), studies focused on the dosage and sequence of cisplatin administration are currently particularly featured. Amongst these, a study on dosage reduction in human papilloma virus (HPV)-positive patients was presented. Other investigations addressed substances as alternatives for cisplatin, particularly carboplatin and targeted therapeutic agents. The comparison of concomitant and sequential CRT (induction chemotherapy (ICT) prior to CRT) is still one of the main topics. In addition, studies modifying the ICT regimen or combining subsequent radiotherapy (RT) with the epidermal growth factor receptor (EGFR) antibody cetuximab were presented. A selection of the most important trials are summarized in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Benson E, Li R, Eisele D et al (2014) The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol 50:565–574

    Article  PubMed Central  PubMed  Google Scholar 

  2. Boelke E, Matuschek C, Gripp S et al (2015) New aspects regarding the induction chemotherapy with TPF and radio chemotherapy in head and neck cancer. J Clin Oncol 33(suppl):6025

    Google Scholar 

  3. Budach V, Keilholz U, Raguse JD et al (2015) Comparison of Standard to Split-Dose TPF Induction Chemotherapy followed by Bio-radiation for LASCC of the Head and Neck: Results of the ICRAT randomized Phase II Study. J Clin Oncol 33(suppl):e17042

    Google Scholar 

  4. Chera BS, Amdur RJ, Tepper JE et al (2015) A prospective phase II trail of de-intensified chemoradiotherapy for low-risk HPV-associated oropharyngeal squamous cell carcinoma. J Clin Oncol 33(suppl):6004

    Google Scholar 

  5. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  CAS  PubMed  Google Scholar 

  6. Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Janoray G, Pointreau Y, Garaud P et al (2015) Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation. J Clin Oncol 33(suppl):6002

    Google Scholar 

  8. Li Q, Guan J, Zhang Y et al (2015) A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). J Clin Oncol 33(suppl):6036

    Google Scholar 

  9. Massarelli E, Haddad RI, Lee JJ et al (2015) Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). J Clin Oncol 33(suppl):6001

    Google Scholar 

  10. Mesia R, Saenz JaG, Lozano A et al (2015) Phase II study with conventional radiotherapy (RT) + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study. J Clin Oncol 33(suppl):6037

    Google Scholar 

  11. Mohamed A, Schrapp K, Owonikoko TK et al (2015) Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis. J Clin Oncol 33(suppl):6055

    Google Scholar 

  12. Pignon J-P, Maître AL, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14

    Article  PubMed  Google Scholar 

  13. Popovtzer A, Ben-Aharon I, Cohen EEW et al (2015) Is there a role for induction chemotherapy in the setting of concomitant chemoradiation in locally advanced head and neck cancer: A systematic review and meta-analysis of randomized controlled trials. J Clin Oncol 33(suppl):6068

    Google Scholar 

  14. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and Fluorouracil alone or with Docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

    Article  CAS  PubMed  Google Scholar 

  15. Siu LL, Waldron JN, Chen BE et al (2015) Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. J Clin Oncol 33(suppl):6000

    Google Scholar 

  16. Spreafico A, Huang SH, Xu W et al (2015) Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (−) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC). J Clin Oncol 33(suppl):6020

    Google Scholar 

  17. Vermorken JB, Remenar E, Van Herpen C et al (2007) Cisplatin, Fluorouracil, and Docetaxel in Unresectable head and neck cancer. N Engl J Med 357:1695–1704

    Article  CAS  PubMed  Google Scholar 

  18. Villaflor VM, Cohen EEW, Melotek JM et al (2015) Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC). J Clin Oncol 33(suppl):6050

    Google Scholar 

  19. Wong SJ, Li L, Hess LM et al (2015) Utilization and outcomes of low dose versus high dose cisplatin in head and neck cancer patients receiving concurrent radiation. J Clin Oncol 33(suppl):6019

    Google Scholar 

  20. Zhang Y, Guan J, Li Q et al (2015) A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus current radiotherapy for advanced head and neck cancer. J Clin Oncol 33(suppl):6035

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    A. Gliese, C.-J. Busch &  R. Knecht

Authors
  1. A. Gliese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.-J. Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Knecht.

Ethics declarations

Interessenkonflikt

A. Gliese, C.-J. Busch und R. Knecht geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gliese, A., Busch, CJ. & Knecht, R. Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren. HNO 63, 606–611 (2015). https://doi.org/10.1007/s00106-015-0053-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-015-0053-2

Schlüsselwörter

Keywords

Search

Navigation